Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Transl Med ; 7(289): 289ra82, 2015 May 27.
Artigo em Inglês | MEDLINE | ID: mdl-26019218

RESUMO

Current therapies for acute myeloid leukemia (AML) are largely ineffective, and AML patients may benefit from targeted immunotherapy approaches. MGD006 is a bispecific CD3xCD123 dual-affinity re-targeting (DART) molecule that binds T lymphocytes and cells expressing CD123, an antigen up-regulated in several hematological malignancies including AML. MGD006 mediates blast killing in AML samples, together with concomitant activation and expansion of residual T cells. MGD006 is designed to be rapidly cleared, and therefore requires continuous delivery. In a mouse model of continuous administration, MGD006 eliminated engrafted KG-1a cells (an AML-M0 line) in human PBMC (peripheral blood mononuclear cell)-reconstituted NSG/ß2m(-/-) mice at doses as low as 0.5 µg/kg per day for ~7 days. MGD006 binds to human and cynomolgus monkey antigens with similar affinities and redirects T cells from either species to kill CD123-expressing target cells. MGD006 was well tolerated in monkeys continuously infused with 0.1 µg/kg per day escalated weekly to up to 1 µg/kg per day during a 4-week period. Depletion of circulating CD123-positive cells was observed as early as 72 hours after treatment initiation and persisted throughout the infusion period. Cytokine release, observed after the first infusion, was reduced after subsequent administrations, even when the dose was escalated. T cells from animals with prolonged in vivo exposure exhibited unperturbed target cell lysis ex vivo, indicating no exhaustion. A transient decrease in red cell mass was observed, with no neutropenia or thrombocytopenia. These studies support clinical testing of MGD006 in hematological malignancies, including AML.


Assuntos
Complexo CD3/metabolismo , Subunidade alfa de Receptor de Interleucina-3/metabolismo , Leucemia Mieloide Aguda/imunologia , Linfócitos T/imunologia , Animais , Antígenos CD , Medula Óssea/patologia , Morte Celular , Proliferação de Células , Citocinas/metabolismo , Relação Dose-Resposta Imunológica , Feminino , Hematopoese , Humanos , Leucemia Mieloide Aguda/patologia , Ativação Linfocitária/imunologia , Contagem de Linfócitos , Macaca fascicularis , Masculino , Camundongos , Ligação Proteica , Engenharia de Proteínas
2.
J Marital Fam Ther ; 35(3): 325-42, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19522785

RESUMO

This article reports on the use of narrative therapy ideas and practices in working with families that are homeless in a shelter-based, multiple-family discussion group program called Fresh Start for Families. It begins with a review of the challenges facing homeless families. It then briefly describes the collaborative methods used to develop the program. It then describes a range of practices and activities that provide opportunities for families to be witnessed in telling their stories of challenge and coping, to help and be helped by other families experiencing similar challenges, to reconnect and strengthen a positive sense of family identity while externalizing the constraining, stigmatizing descriptions associated with homelessness, and to envision and take steps towards their preferred futures.


Assuntos
Comportamento Cooperativo , Terapia Familiar/métodos , Pessoas Mal Alojadas/psicologia , Narração , Psicoterapia de Grupo/métodos , Adaptação Psicológica , Adolescente , Aspirações Psicológicas , Conscientização , Criança , Emoções , Feminino , Humanos , Intenção , Controle Interno-Externo , Satisfação no Emprego , Masculino , Motivação , Cidade de Nova Iorque , Preconceito , Habitação Popular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...